222 related articles for article (PubMed ID: 24415540)
21. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.
Shin HJ; Baker J; Leveson-Gower DB; Smith AT; Sega EI; Negrin RS
Blood; 2011 Aug; 118(8):2342-50. PubMed ID: 21734238
[TBL] [Abstract][Full Text] [Related]
23. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
Front Immunol; 2022; 13():891925. PubMed ID: 35983059
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-10 Gene-Modified Dendritic Cell-Induced Type 1 Regulatory T Cells Induce Transplant-Tolerance and Impede Graft Versus Host Disease After Allogeneic Stem Cell Transplantation.
Wan J; Huang F; Hao S; Hu W; Liu C; Zhang W; Deng X; Chen L; Ma L; Tao R
Cell Physiol Biochem; 2017; 43(1):353-366. PubMed ID: 28869950
[TBL] [Abstract][Full Text] [Related]
25. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
26. Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.
Monlish DA; Beezhold KJ; Chiaranunt P; Paz K; Moore NJ; Dobbs AK; Brown RA; Ozolek JA; Blazar BR; Byersdorfer CA
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34291733
[TBL] [Abstract][Full Text] [Related]
27. Tolerance induction between two different strains of parental mice prevents graft-versus-host disease in haploidentical hematopoietic stem cell transplantation to F1 mice.
Guo Y; Zhang L; Wan S; Sun X; Wu Y; Yu XZ; Xia CQ
Biochem Biophys Res Commun; 2014 Apr; 446(4):1035-41. PubMed ID: 24661874
[TBL] [Abstract][Full Text] [Related]
28. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
29. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ
Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells.
Ukena SN; Geffers R; Buchholz S; Stadler M; Franzke A
Transpl Immunol; 2012 Dec; 27(4):179-83. PubMed ID: 22889700
[TBL] [Abstract][Full Text] [Related]
31. T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice.
Fu J; Wu Y; Nguyen H; Heinrichs J; Schutt S; Liu Y; Liu C; Jin J; Anasetti C; Yu XZ
J Immunol; 2016 Apr; 196(7):3168-79. PubMed ID: 26903480
[TBL] [Abstract][Full Text] [Related]
32. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells.
Veenstra RG; Taylor PA; Zhou Q; Panoskaltsis-Mortari A; Hirashima M; Flynn R; Liu D; Anderson AC; Strom TB; Kuchroo VK; Blazar BR
Blood; 2012 Jul; 120(3):682-90. PubMed ID: 22677125
[TBL] [Abstract][Full Text] [Related]
33. Host-derived CD8⁺ dendritic cells protect against acute graft-versus-host disease after experimental allogeneic bone marrow transplantation.
Weber M; Rudolph B; Stein P; Yogev N; Bosmann M; Schild H; Radsak MP
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1696-704. PubMed ID: 25132527
[TBL] [Abstract][Full Text] [Related]
34. Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease.
Pérol L; Martin GH; Maury S; Cohen JL; Piaggio E
Immunol Lett; 2014 Dec; 162(2 Pt B):173-84. PubMed ID: 25445496
[TBL] [Abstract][Full Text] [Related]
35. Early Notch Signals Induce a Pathogenic Molecular Signature during Priming of Alloantigen-Specific Conventional CD4
Chung J; Radojcic V; Perkey E; Parnell TJ; Niknafs Y; Jin X; Friedman A; Labrecque N; Blazar BR; Brennan TV; Siebel CW; Maillard I
J Immunol; 2019 Jul; 203(2):557-568. PubMed ID: 31182480
[TBL] [Abstract][Full Text] [Related]
36. Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI.
Li N; Chen Y; He W; Yi T; Zhao D; Zhang C; Lin CL; Todorov I; Kandeel F; Forman S; Zeng D
Blood; 2009 Jan; 113(4):953-62. PubMed ID: 18922852
[TBL] [Abstract][Full Text] [Related]
37. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
38. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.
Nguyen VH; Shashidhar S; Chang DS; Ho L; Kambham N; Bachmann M; Brown JM; Negrin RS
Blood; 2008 Jan; 111(2):945-53. PubMed ID: 17916743
[TBL] [Abstract][Full Text] [Related]
39. Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.
Sadeghi B; Al-Hashmi S; Hassan Z; Rozell B; Concha H; Lundmark C; Grönvik KO; Abedi-Valugerdi M; Hassan M
Clin Dev Immunol; 2010; 2010():142943. PubMed ID: 21197273
[TBL] [Abstract][Full Text] [Related]
40. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
